Overview

RGD PET/MRI in Sporadic Vestibular Schwannoma

Status:
Unknown status
Trial end date:
2021-01-02
Target enrollment:
0
Participant gender:
All
Summary
The aim of this non-randomised, prospective study is to investigate the applicability and prognostic value of angiogenesis PET/MR with the radioligand 68Ga-NODAGA- E[c(RGDyK)]2 in patients with sporadic Vestibuarl Schwannomas.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Rigshospitalet, Denmark
Criteria
Inclusion Criteria:

- Patients > 18 years with MRI verified sporadic vestibular schwannomas

- Patients > 18 år whom max has been in watchful waiting regime in 12 months and/or max.
received 1 follow-up MRI scan.

- Must be able to read and understand the patient information in Danish and to give
informed consent

Exclusion Criteria:

- Pregnancy

- Breast-feeding

- Weight more than the maximum weight limit for the PET/MR bed of the scanner (140 kg)

- History of allergic reaction attributable to compounds of similar chemical or biologic
composition to 68Ga-NODAGA-E[c(RGDyK)]2

- Recent systemic treatment with steroids

- Hormone treatment incl. birth control pills.

- Claustrofobia

- Non-MRI compatible implants.